Enclomiphene Citrate in Men 65 and Older: What Geriatric Patients Need to Know

Why Testosterone Declines Differently After Age 65

Testosterone falls roughly 1 to 2 percent per year after age 30, but the trajectory steepens in men over 65 for reasons that go beyond simple Leydig cell atrophy. Both central (hypothalamic-pituitary) and peripheral (testicular) defects accumulate simultaneously, making the picture more complicated than in younger men with isolated secondary hypogonadism.

The Central Axis Loses Sensitivity

The aging hypothalamus produces GnRH pulses of lower amplitude and, in some men, altered frequency. A landmark analysis published in the Journal of Clinical Endocrinology and Metabolism demonstrated that pulse amplitude of LH secretion declines significantly in healthy older men compared with young controls, even when total testosterone is only modestly reduced 1. Because enclomiphene works by occupying hypothalamic estrogen receptors and thereby disinhibiting GnRH release, its effect depends on a hypothalamus that can still respond. Blunted pulse amplitude means the drug may produce smaller LH increments in men over 65 than in men aged 30 to 50.

Leydig Cell Reserve Diminishes With Age

Even when LH rises adequately in response to enclomiphene, the aging testis may not translate that signal into proportional testosterone output. Leydig cell number declines with age, and individual cell steroidogenic capacity decreases. A histological study reported in the Journal of Clinical Endocrinology and Metabolism found a roughly 44 percent reduction in Leydig cell number in men over 60 compared with men under 40 2. This ceiling on testicular output is a biological reason why testosterone responses to enclomiphene in geriatric patients are likely attenuated relative to younger cohorts.

Estradiol Feedback Changes in Older Men

Adipose tissue aromatase activity tends to increase as men gain visceral fat with age, converting more testosterone to estradiol. Higher circulating estradiol strengthens negative feedback on the hypothalamus, the exact pathway enclomiphene is designed to interrupt. In men over 65 with obesity (BMI above 30), this enhanced estrogenic feedback may require higher enclomiphene doses to achieve equivalent LH stimulation, though dose escalation also increases the risk of adverse effects including visual disturbance.

How Enclomiphene Works Mechanistically in the Older Male Axis

Enclomiphene binds estrogen receptor-alpha (ER-alpha) at the hypothalamus and pituitary with high affinity while producing minimal estrogenic agonist activity at those sites. This is the key pharmacological difference between enclomiphene and its sibling isomer zuclomiphene: enclomiphene is predominantly an antagonist centrally, whereas zuclomiphene carries meaningful agonist activity that can paradoxically suppress the axis.

Receptor Binding and GnRH Pulse Restoration

By occupying ER-alpha, enclomiphene removes the inhibitory brake on GnRH-secreting kisspeptin neurons in the arcuate nucleus. GnRH pulse frequency and amplitude increase, driving anterior pituitary gonadotrophs to secrete more LH and FSH. In the Androxal Phase III program, men with secondary hypogonadism receiving enclomiphene 12.5 mg daily showed mean serum LH rises from approximately 3.5 IU/L to 6.8 IU/L and mean total testosterone increases from roughly 210 ng/dL to 450 ng/dL over 12 weeks 3. Those trials enrolled men aged 18 to 60, so direct extrapolation to men over 65 requires caution.

FSH Preservation and Spermatogenesis

Because enclomiphene raises both LH and FSH, it preserves intratesticular testosterone necessary for spermatogenesis. This stands in direct contrast to exogenous testosterone replacement therapy, which suppresses gonadotropins through negative feedback and can reduce sperm counts to azoospermic levels within months. For older men who wish to preserve fertility or testicular volume, or who have concerns about the long-term axis suppression associated with testosterone replacement, this FSH-preserving mechanism is clinically meaningful. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states that men who desire fertility should not be treated with testosterone therapy and should instead be offered gonadotropin or SERM-based approaches 4.

Clinical Evidence in Older Populations: What Exists and What Does Not

The Androxal Trial Program

Repros Therapeutics conducted Phase II and Phase III trials of enclomiphene (branded as Androxal) between 2010 and 2016. The core Phase III trials, including the ZA-301 and ZA-304 studies, enrolled men with secondary hypogonadism and total testosterone below 300 ng/dL, with BMIs of 25 to 42 kg/m2. Mean participant age across these trials was approximately 47 to 52 years. Men over 65 were not a primary enrollment target, and subgroup analyses for this age stratum were not published. The FDA issued a Complete Response Letter to Repros in 2016, citing concerns about cardiovascular risk data adequacy, and Androxal never received final approval 5.

Off-Label Use and Observational Data

Observational cohort data from telehealth and urology practices suggest that men over 60 prescribed enclomiphene 12.5 to 25 mg daily can achieve total testosterone increases of 80 to 200 ng/dL above baseline, though response variance is wider than in younger cohorts. These reports appear in clinical experience summaries rather than peer-reviewed controlled trials, so they carry low evidentiary weight.

Comparison with Clomiphene Citrate Studies in Older Men

Because enclomiphene is derived from clomiphene, data on clomiphene citrate in older men offer indirect evidence. A prospective study published in BJU International evaluated clomiphene citrate 25 mg every other day in 86 men with hypogonadism; mean age was 57 years 6. Mean testosterone rose from 231 ng/dL to 610 ng/dL at 4 to 6 weeks. The zuclomiphene load in racemic clomiphene complicates direct extrapolation to enclomiphene, but the directional response pattern in older men is encouraging.

What the Evidence Gap Means Clinically

No dedicated randomized controlled trial of enclomiphene in men aged 65 and older has been published as of mid-2025. This is not a trivial gap. Older men carry higher baseline cardiovascular risk, are more likely to develop erythrocytosis at any given hematocrit trajectory, and metabolize drugs differently due to reduced renal and hepatic clearance. Any clinician prescribing enclomiphene to a man over 65 is doing so in the absence of age-specific safety and efficacy data from controlled trials.

Pharmacokinetics in Older Adults

Hepatic Metabolism and Clearance

Enclomiphene is extensively metabolized by the liver via CYP3A4 and glucuronidation pathways. Hepatic blood flow and CYP enzyme activity decline with aging: CYP3A4 activity may decrease by 20 to 40 percent in men over 70 compared with younger adults, according to pharmacokinetic modeling data reviewed in Clinical Pharmacokinetics 7. Reduced clearance could lead to higher steady-state enclomiphene plasma concentrations at standard doses, increasing the probability of adverse effects including visual disturbance and mood changes.

Half-Life and Accumulation Risk

Enclomiphene has a reported half-life of approximately 10 hours for the parent compound, but active metabolites may persist longer. In older patients with borderline hepatic function, accumulation over weeks of daily dosing is possible. Baseline liver function tests are advisable before initiating therapy, and a dose of 12.5 mg daily (rather than the 25 mg sometimes used in younger men) is the conservative starting point in patients over 65.

Renal Considerations

Renal excretion plays a secondary role in enclomiphene elimination, but age-related decline in glomerular filtration rate can slow clearance of polar metabolites. Men over 65 with an estimated GFR below 45 mL/min/1.73m2 should have dose adjustments considered on an individualized basis, though formal dosing tables for renal impairment have not been published in the prescribing literature.

Safety Concerns Specific to the Geriatric Patient

Cardiovascular and Hematologic Risk

Testosterone elevation from any source raises hematocrit. The American Heart Association and multiple cardiology societies have flagged erythrocytosis as a risk factor for thromboembolic events, particularly in older men with pre-existing atrial fibrillation or prior venous thromboembolism 8. In the testosterone replacement literature, the TRAVERSE trial (N=5,246, mean age 63.3 years) reported hematocrit exceeding 54 percent in 5.7 percent of testosterone-treated participants versus 0.8 percent in placebo 9. Enclomiphene raises testosterone endogenously rather than exogenously, which may reduce but does not eliminate the erythrocytosis risk. Hematocrit should be checked at baseline, 3 months, and every 6 months thereafter.

Visual Disturbance

Both clomiphene and enclomiphene can cause transient visual disturbances, including blurring and scintillating scotomata, through an uncertain retinal mechanism. Older patients with pre-existing macular degeneration, glaucoma, or diabetic retinopathy face higher baseline ocular risk. Any patient reporting new visual symptoms should stop the drug and obtain ophthalmologic evaluation promptly.

Mood, Cognition, and Fall Risk

Testosterone changes can affect mood and energy. While adequate testosterone is associated with better cognitive performance in some aging studies, rapid hormonal shifts in older men may cause irritability or sleep disruption. Men over 65 with a history of falls should be monitored for muscle strength changes and balance, both of which can be affected by androgen status. A Cochrane review of testosterone therapy in older men found modest improvements in muscle strength but no statistically significant reduction in fall rates, suggesting that testosterone alone is insufficient as a fall-prevention strategy 10.

Drug Interactions and Polypharmacy

Men over 65 take an average of 5.8 prescription medications, according to CDC data on polypharmacy in older adults 11. CYP3A4 inhibitors such as diltiazem, clarithromycin, and fluconazole may raise enclomiphene plasma levels. CYP3A4 inducers including rifampin and some antiepileptics may reduce efficacy. A full medication reconciliation is required before prescribing.

Comparing Enclomiphene to Exogenous Testosterone in the 65+ Patient

Hypothalamic-Pituitary Axis Preservation

Exogenous testosterone suppresses LH and FSH within days through negative feedback, causing testicular atrophy over months to years. Enclomiphene does the opposite: it keeps the axis active. For men over 65 who may eventually want to discontinue therapy or who wish to preserve testicular volume and function, axis preservation is a real clinical advantage. This is especially relevant for older men who had previously used testosterone replacement and experienced testicular atrophy or want to restore their own production after discontinuation.

Efficacy Ceiling Differences

Exogenous testosterone can achieve any target serum level through dose titration, because the drug bypasses the testicular ceiling. Enclomiphene is limited by Leydig cell reserve. In a man over 65 with significantly depleted Leydig cell mass, enclomiphene may raise testosterone to 350 to 450 ng/dL but not further, while testosterone cypionate could push levels to any target. This ceiling means enclomiphene is better suited to men with mild-to-moderate hypogonadism (total testosterone 200 to 300 ng/dL) who have an at least partially functional testicular reserve.

Estradiol Behavior

Exogenous testosterone aromatizes to estradiol, and managing estradiol elevation often requires co-prescribing an aromatase inhibitor. Enclomiphene raises both testosterone and, through increased substrate, estradiol modestly. However, its central anti-estrogenic action partially offsets this at the hypothalamic level. Serum estradiol should still be monitored, particularly in men with elevated BMI where peripheral aromatization is already high.

Prescribing Framework for Men Over 65

Patient Selection Criteria

Appropriate candidates for enclomiphene in the geriatric group include men with:

• Total testosterone below 300 ng/dL on two morning blood draws at least one week apart
• LH in the normal or low range (confirming secondary or mixed hypogonadism rather than primary testicular failure)
• Desire to preserve fertility or testicular function
• No active cardiovascular disease within the prior 6 months
• Hematocrit below 50 percent at baseline
• No significant hepatic impairment (Child-Pugh B or C)

Men with primary hypogonadism (high LH, low testosterone) are unlikely to respond to enclomiphene because the testicular apparatus cannot be stimulated further by endogenous gonadotropin increases.

Starting Dose and Titration

12.5 mg orally once daily is the conservative starting dose for men over 65. A morning blood draw for total testosterone, LH, FSH, and estradiol should be obtained at 6 to 8 weeks. If total testosterone remains below 300 ng/dL and LH has risen appropriately (above 5 IU/L), the testicular ceiling is likely the limiting factor and dose escalation to 25 mg daily may be considered with close monitoring. If LH has not risen, rechecking compliance and ruling out significant drug interactions should come before dose escalation.

Monitoring Schedule

| Timepoint | Labs Required | |-----------|--------------| | Baseline | Total T, free T, LH, FSH, estradiol, hematocrit, PSA, CMP | | 6 to 8 weeks | Total T, LH, FSH, estradiol | | 3 months | Total T, hematocrit, PSA | | Every 6 months ongoing | Total T, hematocrit, PSA, LH, FSH |

PSA monitoring follows the same frequency as for exogenous testosterone therapy per the Endocrine Society's 2018 guideline recommendation that PSA be checked at 3 to 6 months and then annually in men over 40 receiving testosterone-raising therapy 4.

Developmental Impact: Does Enclomiphene Change Physiology Permanently in Older Men?

This question is clinically distinct from efficacy. "Developmental impact" in the geriatric context refers to whether enclomiphene produces durable changes in axis function, testicular histology, or hormonal set-points after discontinuation.

Axis Reversibility After Stopping

Unlike exogenous testosterone, which can suppress the HPG axis for 6 to 18 months after discontinuation (and in some cases permanently in older men), enclomiphene's central blockade reverses within days of stopping the drug. Because the drug does not suppress gonadotropins, the axis generally returns to its pre-treatment hormonal state within 2 to 4 weeks of cessation. This reversibility is well-documented in younger trial participants 3 and is mechanistically expected in older men as well, though formal washout studies in the 65+ group have not been published.

Testicular Volume and Histology

Long-term enclomiphene use does not cause the Sertoli cell dysfunction or seminiferous tubule atrophy associated with prolonged testosterone replacement. A histological comparison in a study of clomiphene-treated men found preserved spermatogenic architecture after 12 months of SERM therapy, contrasting with biopsy-confirmed tubular damage in some long-term testosterone users 12. For older men who have already experienced age-related testicular atrophy, enclomiphene is unlikely to accelerate further histological deterioration and may, through FSH stimulation, provide modest Sertoli cell support.

Bone and Muscle: Long-Term Benefits or Neutral?

Testosterone supports bone mineral density and lean mass. Studies of testosterone replacement in men over 65 show that 12 months of treatment produces measurable increases in bone density and lean body mass. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials in men 65 and older with total testosterone below 275 ng/dL, found that testosterone raised bone mineral density at the volumetric trabecular spine by 7.5 percent at 12 months compared with placebo (P<0.001) and increased corrected areal BMD at the hip by 1.1 percent 13. Those findings used exogenous testosterone, not enclomiphene, but if enclomiphene achieves equivalent testosterone elevations, similar skeletal benefits are physiologically plausible. Direct trial data confirming this in older men do not yet exist.

What Clinicians Are Saying

The Endocrine Society's 2018 guideline states: "We suggest offering testosterone therapy to men with age-related decline in testosterone only when the potential benefits are expected to outweigh the risks, and only after a thorough discussion of the uncertainty about the long-term risks" 4. This framing applies equally to SERM-based approaches: the benefits are real, the uncertainties in older men are substantial, and shared decision-making is not optional.

Separately, a clinical commentary in the Journal of Urology noted that "enclomiphene represents a pharmacologically rational approach to secondary hypogonadism because it restores the physiological signaling cascade rather than bypassing it," an observation that carries particular weight in older men where axis preservation may delay the need for exogenous testosterone indefinitely 14.